137 related articles for article (PubMed ID: 19825933)
1. Clinical trial for Fabry disease faces continuing hurdles.
Silversides A
CMAJ; 2009 Nov; 181(11):E251-2. PubMed ID: 19825933
[No Abstract] [Full Text] [Related]
2. [Enzyme therapy in Fabry disease: when scarcity of one enzyme illustrates the vulnerability of biotech].
Lidove O; Choukroun G; Bekri S; Viot G; Tsimaratos M; Joly D
Presse Med; 2010 May; 39(5):527-9. PubMed ID: 20194001
[No Abstract] [Full Text] [Related]
3. Agalsidase alfa: specific treatment for Fabry disease.
Mehta A
Hosp Med; 2002 Jun; 63(6):347-50. PubMed ID: 12096664
[TBL] [Abstract][Full Text] [Related]
4. Fabry disease: the need to stratify patient populations to better understand the outcome of enzyme replacement therapy.
Germain DP
Clin Ther; 2007; 29 Suppl A():S17-8. PubMed ID: 17580237
[No Abstract] [Full Text] [Related]
5. Enzyme replacement in Anderson-Fabry disease.
Bengtsson BA; Johansson JO; Hollak C; Linthorst G; FeldtRasmussen U
Lancet; 2003 Jan; 361(9354):352. PubMed ID: 12559898
[No Abstract] [Full Text] [Related]
6. Fabry trial set to answer "political problem".
Silversides A
CMAJ; 2009 Sep; 181(6-7):365-6. PubMed ID: 19752140
[No Abstract] [Full Text] [Related]
7. Pediatrics: implementing the promise of early intervention for Fabry disease.
Raas-Rothschild A
Clin Ther; 2007; 29 Suppl A():S6. PubMed ID: 17580239
[No Abstract] [Full Text] [Related]
8. Agalsidase: a second look. With hindsight: full data challenge efficacy.
Prescrire Int; 2003 Oct; 12(67):168-71. PubMed ID: 14619828
[No Abstract] [Full Text] [Related]
9. Agalsidase beta (Fabrazyme) for Fabry disease.
Med Lett Drugs Ther; 2003 Sep; 45(1165):74-5. PubMed ID: 12968124
[No Abstract] [Full Text] [Related]
10. Enzyme therapy for Fabry patients in jeopardy.
Silversides A
CMAJ; 2009 Sep; 181(6-7):E120. PubMed ID: 19752137
[No Abstract] [Full Text] [Related]
11. Fabry disease: clinical outcomes of agalsidase enzyme replacement therapies.
Wanner C
Int J Clin Pract; 2007 Jul; 61(7):1234-5; author reply 1235. PubMed ID: 17577304
[No Abstract] [Full Text] [Related]
12. Agalsidase treatment for Fabry disease: uses and rivalries.
Schiffmann R
Genet Med; 2010 Nov; 12(11):684-5. PubMed ID: 20975568
[No Abstract] [Full Text] [Related]
13. [Fabry disease: new clinical research--current therapeutic perspectives].
Beck M
Wien Klin Wochenschr; 2003 Apr; 115(7-8):215-7. PubMed ID: 12778772
[No Abstract] [Full Text] [Related]
14. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.
Mehta A; Beck M; Kampmann C; Frustaci A; Germain DP; Pastores GM; Sunder-Plassmann G
Mol Genet Metab; 2008; 95(1-2):114-5. PubMed ID: 18701330
[No Abstract] [Full Text] [Related]
15. Enzyme replacement therapy and Fabry kidney disease: quo vadis?
Warnock DG
J Am Soc Nephrol; 2007 May; 18(5):1368-70. PubMed ID: 17429046
[No Abstract] [Full Text] [Related]
16. Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?
Hollak CE; Linthorst GE
Mol Genet Metab; 2009 Jan; 96(1):1-3. PubMed ID: 19062323
[No Abstract] [Full Text] [Related]
17. Enzyme replacement in Fabry disease: the essence is in the kidney.
Schiffmann R
Ann Intern Med; 2007 Jan; 146(2):142-4. PubMed ID: 17179053
[No Abstract] [Full Text] [Related]
18. Does enzyme replacement therapy improve symptoms of Fabry disease in patients undergoing dialysis?
Banikazemi M; Desnick RJ
Nat Clin Pract Nephrol; 2006 Feb; 2(2):72-3. PubMed ID: 16932395
[No Abstract] [Full Text] [Related]
19. Fabry disease: dose matters.
Warnock DG; Mauer M
J Am Soc Nephrol; 2014 Apr; 25(4):653-5. PubMed ID: 24556355
[No Abstract] [Full Text] [Related]
20. First treatment for Fabry's disease.
FDA Consum; 2003; 37(4):4. PubMed ID: 12971327
[No Abstract] [Full Text] [Related]
[Next] [New Search]